Nerviano Medical Sciences will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2016, April 16-20, New Orleans, Louisiana, USA.
New data will be presented regarding a novel potent and highly selective PARP-1 inhibitor, that potentially represents a significant advancement over currently available agents, which target both PARP-1 and -2. NMS-P293 is selectively active on tumor cell lines defective in the HR DNA repair pathway, such as BRCA and pTEN mutated lines, while sparing DNA repair proficient cells and normal myelocytes. Its highly favorable preclinical characteristics make this compound a promising candidate for further development.
The second presentation regards novel, potent and selective ATP-competitive MELK kinase inhibitors identified by means of high-throughput screening of the Nerviano Medical Sciences proprietary compound collection. MELK gene expression levels correlate inversely with poor prognosis in breast cancer, prostate cancer and glioblastoma patients, with recent findings also underlining the oncogenic role of this kinase in triple negative breast cancer (TNBC), a category of high-grade and invasive tumors.
Presentation title: NMS-P293, a novel potent and selective PARP-1 inhibitor with high antitumor efficacy and tolerability
Authors: Alessia Montagnoli et al
Meeting: AACR Annual Meeting 2016, Abstract number 1223
Presentation Time: Monday, Apr 18, 2016, 8:00 AM -12:00 PM
Presentation title: 3795: Novel and selective MELK kinase inhibitors active in breast cancer cell lines
Authors: Patrizia Carpinelli et al
Meeting: AACR Annual Meeting 2016, Abstract number 3795
Presentation Time: Tuesday, Apr 19, 2016, 1:00 PM - 5:00 PM
The full abstracts can be found on the conference website: http://www.aacr.org